

Real-World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom

In the article by Linde et al, “Real-World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom,” which published online November 12, 2019, and appeared in the November 19, 2019 issue of the journal (*J Am Heart Assoc.* 2019;8:e012655. DOI: 10.1161/JAHA.119.012655), a correction to the supplemental material was needed.

The supplemental material is correct in the HTML version of the article, but an incorrect supplemental PDF has been appended to the article PDF. The PDF appended to the article has now been corrected.

The publisher regrets the error.

The online version of the article has been updated and is available at <https://www.ahajournals.org/doi/full/10.1161/JAHA.119.012655>

J Am Heart Assoc. 2019;8:e014500. DOI: 10.1161/JAHA.119.014500.

© 2019 The Authors and Health Economics and Outcomes Research Ltd. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.